Table 1.

Summary of participant characteristics

DCS vs MRIVoxelotor
Age, y 14 (11-17) 9 (7-12) 
Male, n (%) 2 (25) 5 (63) 
Weight, kg 60 (45-71) 33 (23-43) 
Hb, g/dL 9.9 (8.3-11.1) 9.1 (8.2-9.9) 
% Reticulocyte count — 8.1 (5.2-11.0) 
% White blood cell count — 7.5 (5.0-10.0) 
LDH, U/L — 455 (268-571) 
Bilirubin, μmol/L — 2.3 (1.4-3.2) 
HbF, % — 22.4 (10.7-34.1) 
HbSS genotype, n (%) 8 (100) 8 (100) 
Current hydroxyurea use, n (%) 7 (88) 8 (100) 
DCS vs MRIVoxelotor
Age, y 14 (11-17) 9 (7-12) 
Male, n (%) 2 (25) 5 (63) 
Weight, kg 60 (45-71) 33 (23-43) 
Hb, g/dL 9.9 (8.3-11.1) 9.1 (8.2-9.9) 
% Reticulocyte count — 8.1 (5.2-11.0) 
% White blood cell count — 7.5 (5.0-10.0) 
LDH, U/L — 455 (268-571) 
Bilirubin, μmol/L — 2.3 (1.4-3.2) 
HbF, % — 22.4 (10.7-34.1) 
HbSS genotype, n (%) 8 (100) 8 (100) 
Current hydroxyurea use, n (%) 7 (88) 8 (100) 

Data are reported as median (IQR) or count (percentage) for the DCS validation against MRI cohort (n = 8, first column) and voxelotor cohort at the time of screening (n = 8, second column).

HbF, fetal hemoglobin.

or Create an Account

Close Modal
Close Modal